棘霉素（NSC 526417）用于复发性和转移性宫颈非鳞状细胞癌。妇科肿瘤学组的一项II期试验。
Echinomycin (NSC 526417) in recurrent and metastatic nonsquamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
作者信息
Muss H B, Blessing J A, Hanjani P, Malfetano J H, Kemp G M, Webster K
机构信息
Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.
出版信息
Am J Clin Oncol. 1992 Aug;15(4):363-4. doi: 10.1097/00000421-199208000-00019.
Eighteen evaluable patients with recurrent or metastatic nonsquamous carcinoma of the uterine cervix were treated with 1,500 micrograms/m2 of echinomycin every 4 weeks. Seven patients had received prior chemotherapy. There was one complete response (5.6%), 95% confidence interval for response of 0-27%. The major toxicity was nausea and vomiting, which was moderate to severe in eight patients. Myelosuppression was minimal. Echinomycin in this dose and schedule displays minimal activity in patients with advanced nonsquamous carcinoma of the cervix.
18例可评估的复发性或转移性子宫颈非鳞状细胞癌患者接受了每4周1500微克/平方米的棘霉素治疗。7例患者曾接受过化疗。有1例完全缓解（5.6%），缓解的95%置信区间为0 - 27%。主要毒性为恶心和呕吐，8例患者中为中至重度。骨髓抑制轻微。该剂量和疗程的棘霉素在晚期子宫颈非鳞状细胞癌患者中显示出最小活性。
Zotero 插件